1-17 of 17
Liling Zhang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas

Yuqin Song, Zengjun Li, Huijing Wu, Jie Jin, Hui Zhou, Keshu Zhou, Liling Zhang, Zhigang Peng, Zhiye Zhang, Hong Cen, Youchao Jia, Yuerong Shuang, Zhiming Li, Haiyan Yang, Liqun Zou, Zhifeng Li, Zhihui Zhang, Junmin Li, Junning Cao, Lugui Qiu, Shaojie Wu, Tiejun Gong, Xiaohong Xu, Zhen Wang, Jun Zhu
Journal: Blood
Blood (2023) 142 (Supplement 1): 306.
https://doi.org/10.1182/blood-2023-180137
Published: 2023
Journal Articles

A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial of HH2853 in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma

Huangming Hong, Mingzhi Zhang, Zhigang Peng, Jianzhen Shen, Yuerong Shuang, Hui Zhou, Hongqiang Guo, He Huang, Fei Li, Zhengzi Qian, Lihong Liu, Liang Wang, Wei Yang, Liling Zhang, Pengcheng He, Shen Qian, Fugen Li, Meng Li, Tongyu Lin
Journal: Blood
Blood (2023) 142 (Supplement 1): 304.
https://doi.org/10.1182/blood-2023-180372
Published: 2023
Journal Articles

Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Ningjing Lin, Xiuhua Sun, Hui Zhou, Liqun Zou, Keshu Zhou, Lihong Liu, Haiyan Yang, Kai HU, Qingqing Cai, Yao Liu, Jie Jin, Liling Zhang, Wenyu Li, Ye Guo, Wei Yang, Feng Luo, Yanyan Li, Mengqi Zhang, Feinan Lu, Yuqin Song, Jun Zhu
Journal: Blood
Blood (2023) 142 (Supplement 1): 4469.
https://doi.org/10.1182/blood-2023-173645
Published: 2023
Journal Articles

Update of Swatch Study: Selinxor Combined with Lenalidomide and Rituximab (R2) in Adults with Diffuse Large B Cell Lymphoma (DLBCL) and Indolent Non-Hodgkin's Lymphoma (iNHL)

Li Wang, Zhiming Li, Lina Zhang, Liling Zhang, Jay Mei, Wei Li Zhao
Journal: Blood
Blood (2023) 142 (Supplement 1): 6235.
https://doi.org/10.1182/blood-2023-180535
Published: 2023
Journal Articles

Phase 2 Search Study：XPO1 Inhibitor (ATG-010) Monotherapy in Heavily Pretreated Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Yuqin Song, Qingqing Cai, Qingyuan Zhang, Xiuhua Sun, Haiyan Yang, Zhihua Yao, Liqun Zou, Liling Zhang, Junning Cao, Tingyu Wang, Lanfang Li, Yao Liu, Hongmei Jing, Sujun Gao, Kaiyang Ding, Bingshan Liu, Jun Zhao, Jun Zhu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6234.
https://doi.org/10.1182/blood-2023-180413
Published: 2023
Journal Articles

PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r ENKTL): Updates of the Phase Ib/II Scent Study

Gao Yan, Liling Zhang, Wenyu Li, Xu Wei, Ru Feng, Xue-Ping Li, Yu Chen, Huijing Wu, Xiaoxiao Wang, Bing Bai, Huiqiang Huang
Journal: Blood
Blood (2023) 142 (Supplement 1): 1689.
https://doi.org/10.1182/blood-2023-186252
Published: 2023
Journal Articles

Phase 2 Study of Golidocitinib, a JAK1 Selective Inhibitor, As Maintenance Therapy in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy (JACKPOT26)

Jie Jin, Qingqing Cai, Liling Zhang, Liqun Zou, Zengjun Li, Huijing Wu, Keshu Zhou, Lihua Qiu, Liping Su, Kaiyang Ding, Hui Zhou, Li Yu, Fei Li, Qing Xiao, Wenyu Li, Lie Lin, Erhua Wang, Lijia Chen
Journal: Blood
Blood (2023) 142 (Supplement 1): 4430.
https://doi.org/10.1182/blood-2023-185543
Published: 2023
Journal Articles

Pirtobrutinib, a Non-Covalent (reversible) BTK Inhibitor, in Mantle Cell Lymphoma Patients Previously Treated with a Covalent BTK Inhibitor: Results from a China Phase 2 Study

Yuqin Song, Shuhua Yi, Haiyan Yang, Ru Feng, Huiqiang Huang, Qingyuan Zhang, Yanyan Liu, Ye Guo, Huilai Zhang, Liling Zhang, Yijiao Qian, JianKun Zhu, Jun Zhu
Journal: Blood
Blood (2023) 142 (Supplement 1): 3636.
https://doi.org/10.1182/blood-2023-173287
Published: 2023
Journal Articles

Golidocitinib in Treating Refractory or Relapsed Peripheral T- Cell Lymphoma: Full Analysis of the Multinational Pivotal Study Results (JACKPOT8)

Yuqin Song, Luis Malpica, Qingqing Cai, Weili Zhao, Keshu Zhou, Jianqiu Wu, Huilai Zhang, Kaiyang Ding, Yao Liu, Zengjun Li, Neha Mehta-Shah, Liling Zhang, Meifang Zheng, Jie Jin, Haiyan Yang, Yuerong Shuang, Dok Hyun Yoon, Sujun Gao, Wenyu Li, Zhimin Zhai, Liqun Zou, Yaming Xi, Youngil Koh, Fei Li, Miles Prince, Hui Zhou, Lie Lin, Hui Liu, Zhenfan Yang, Won Seog Kim, Jun Zhu
Journal: Blood
Blood (2023) 142 (Supplement 1): 305.
https://doi.org/10.1182/blood-2023-172962
Published: 2023
Journal Articles

Development and Validation of a Machine-Learning Model to Predict POD24 Risk of Follicular Lymphoma

Jie Zha, Qinwei Chen, Wei Zhang, Hongmei Jing, Jingjing Ye, Haifeng Yu, Shuhua Yi, Caixia Li, Zhong Zheng, Wei Xu, Zhifeng Li, Lingyan Ping, Xiaohua He, Liling Zhang, Ying Xie, Feili Chen, Xiuhua Sun, Liping Su, Huilai Zhang, Zhijuan Lin, Haiyan Yang, Weili Zhao, Lugui Qiu, Zhiming Li, Yuqin Song, Bing Xu
Journal: Blood
Blood (2023) 142 (Supplement 1): 3048.
https://doi.org/10.1182/blood-2023-182812
Published: 2023
Journal Articles

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

Clinical Trials & Observations
Yuqin Song, Hervé Tilly, Shinya Rai, Huilai Zhang, Jie Jin, Hideki Goto, Yasuhito Terui, Ho-Jin Shin, Won Seog Kim, Junning Cao, Jifeng Feng, Hyeon Seok Eom, Tae Min Kim, Xavier Cheng-Hong Tsai, Jyh-Pyng Gau, Hideo Koh, Liling Zhang, Yongping Song, Yu Yang, Wei Li, He Huang, Kiyoshi Ando, Jeff P. Sharman, Laurie H. Sehn, Lilian Bu, Xin Wang, Yanwen Jiang, Jamie Hirata, Calvin Lee, Jun Zhu, Koji Izutsu
Journal: Blood
Blood (2023) 141 (16): 1971–1981.
https://doi.org/10.1182/blood.2022017734
Published: 2023
Includes: Supplemental data
Journal Articles

Preliminary Safety and Efficacy of Zanubrutinib in Combination with Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Huilai Zhang, Keshu Zhou, Ying Cheng, Liling Zhang, Haiyan Yang, Liqun Zou, Junning Cao, Huiqiang Huang, Ye Guo, Zhao Wang, Sha Huang, Zhiyu Liang, Hui Yao, Haiyi Guo, Yiqian Fang, Hongjie Zhu
Journal: Blood
Blood (2022) 140 (Supplement 1): 3750–3752.
https://doi.org/10.1182/blood-2022-155979
Published: 2022
Journal Articles

Efficacy and Safety of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody (SCT400) Combined with CHOP in Patients with Treatment-Naïve Diffuse Large B-Cell Lymphoma: A Multicenter, Randomized, Single-Blind, Parallel Active-Controlled, Phase III Study

Yuankai Shi, QingYuan Zhang, Xiaonan Hong, Zhen Wang, Yuhuan Gao, Liqun Zou, Hong Cen, Lin Gui, Yufu Li, Jifeng Feng, Zhao Wang, Mingzhi Zhang, Chuan Jin, Weihua Zhang, Jianda Hu, Chengyun Zheng, Zhendong Zheng, Liling Zhang, Shaoshui Chen, Yunhong Huang, Yun Tang, Yajie Gao, Miaowang Hao, Xiaoling Li, Chunkang Chang, Haiyan Yang, Hui Wu, Lida Shen, Xiaoyan Ke, Liangming Zhang, Yaming Xi, Linhua Yang, Liangzhi Xie
Journal: Blood
Blood (2021) 138 (Supplement 1): 2480.
https://doi.org/10.1182/blood-2021-149861
Published: 2021
Journal Articles

Invasive Field Radiotherapy Combined with Rituximab Versus Rituximab Alone for Consolidation Therapy in Stage III Follicular Lymphoma Patients Response to R-CHOP Chemotherapy: A Randomized Clinical Study

Tongyu Lin, He Huang, Xiaoqian Li, Huangming Hong, Liqun Zou, Liling Zhang, Zhihui Zhang, Zhongjun Xia, Yongchang Chen, Meiting Chen, Zegeng Chen, Xiaojie Fang, Hongqiang Guo, Ke Xie, Ying Tian, Suxia Lin, Wei Zhang, Yuyi Yao, Fei Pan, Huawei Weng
Journal: Blood
Blood (2021) 138 (Supplement 1): 3531.
https://doi.org/10.1182/blood-2021-146338
Published: 2021
Journal Articles

Efficacy and Safety Analysis of Ibrutinib-Containing Therapy for Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results from a Real-World Study in China

Qingqing Cai, PhD, Huiqiang Huang, MDPhD, Yuchen Zhang, Panpan Liu, MD PhD, Hongmei Jing, MD PhD, Ping Yang, MD PhD, Tongyu Lin, MD PhD, Zhongjun Xia, MDPhD, Zhiming Li, MD PhD, Wenyu Li, PhD, Liye Zhong, MD PhD, Xu Ye, MD PhD, Xueli Jin, MD PhD, Liling Zhang, MD PhD, Huilai Zhang, MD PhD, Xiuhua Sun, MD, Yuyang Tian, MM, Shuyun Ma, MM, Ning Su, MM, Jun Cai, BMBS
Journal: Blood
Blood (2020) 136 (Supplement 1): 1.
https://doi.org/10.1182/blood-2020-136842
Published: 2020
Journal Articles

Anti-PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single-Arm, Phase Ib/II Trial (SCENT)

Yan Gao, MD PhD, Huiqiang Huang, MDPhD, Xiaoxiao Wang, Bing Bai, Liling Zhang, MD PhD, Yin Xiao, Xinxiu Liu, Wenyu Li, PhD, Wei Xu, MD PhD, Ru Feng, Yu Chen, Huijing Wu, Jibin Li, Xue Wu
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–40.
https://doi.org/10.1182/blood-2020-134665
Published: 2020
Journal Articles

Preliminary Results from a Multicenter, Single-Arm, Phase 2 Study of CS1001, an Anti-Programmed Death-Ligand 1 (PD-L1) Human Monoclonal Antibody (mAb), in Patients (pts) with Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma (rr-ENKTL)

Hui-qiang Huang, MD PhD, Rong Tao, MD PhD, Liqun Zou, Hong Cen, MD PhD, Ye Guo, MD PhD, Yunhong Huang, MD PhD, Wenbin Qian, MD PhD, Liling Zhang, MD PhD, Hui Zhou, MD PhD, Yu Yang, MD PhD, Haiyan Yang, Dan Zhu, Teng Fang, PhD, Hangjun Dai, Yueling Wang, Jianxin Yang, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2833.
https://doi.org/10.1182/blood-2019-121865
Published: 2019